Original articleIncidence of Uveal Melanoma in Europe
Section snippets
Definitions and Inclusion Criteria
Cases were defined as patients with ocular melanoma, as identified by the International Classification of Diseases 9 (ICD9) topography codes 190.0 (iris and ciliary body), 190.5 (retina), and 190.6 (choroid) and by the International Classification of Diseases for Oncology morphology codes 8720 to 8780 (melanoma). Based on the suggestion of Stang et al,8 we also considered the inclusion of tumors with an unspecified location in rate computation—namely, code 190.9 (part unspecified).
Contributing
Number of Cases Included for Ocular Subsite
During the 12 years of the study (1983–1994), 7051 melanomas located in the eye, orbit, lacrimal gland, or unspecified ocular sites (codes 190.0–190.9) were recorded by the registries.
Uveal melanoma was the most common location, accounting for 5566 cases (78.9%), including 901 (12.8%) tumors located in the iris or ciliary body (190.0) and 4665 (66.1%) in the choroid or retina subsites (190.5, 190.6). Cases in other locations were 81 (1.1%) in the orbit (190.1), 4 (0.1%) in the lacrimal gland
Discussion
This study has provided data on the incidence of uveal melanoma in several European countries, which may be useful for local policy-making, based on data from cancer registries adhering to EUROCARE in the period 1983 to 1994.
Our study confirms at the European level some previous findings on the effect of demographic variables on uveal melanoma incidence. The pattern of the association of rates with age was similar to that reported in recent studies in the U.S.,7 as rates increased with age and
References (34)
- et al.
Incidence of uveal melanoma in the United States
Ophthalmology
(2003) - et al.
Incidence of surgically treated uveal melanoma by race and ethnicity
Ophthalmology
(1998) - et al.
Survival from rare cancer in adults: a population-based study
Lancet Oncol
(2006) - et al.
EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century
Ann Oncol
(2003) - et al.
The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis
Ann Oncol
(2003) - et al.
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure
Eur J Cancer
(2005) - et al.
“Melanoma 92.” Epidemiological study of uveal melanoma in France
J Fr Ophtalmol
(1995) Trends in incidence of ocular malignant melanoma in Denmark 1943–1982
Int J Cancer
(1987)- et al.
Incidence of choroidal malignant melanoma in Finland in the years 1973–1980
Acta Ophthalmol (Copenh)
(1985) Malignant melanoma of the choroid and the ciliary body 1956–1975 in Halland and GothenburgIncidence, histopathology and prognosis
Acta Ophthalmol (Copenh)
(1983)
Uveal and conjunctival malignant melanoma in Denmark, 1943–97: incidence and validation study
Ophthalmic Epidemiol
Incidence of uveal melanoma in Sweden from 1960 to 1998
Invest Ophthalmol Vis Sci
International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification
Int J Cancer
Incidence of ocular melanoma in Australia from 1990 to 1998
Int J Cancer
Posterior uveal malignant melanoma: temporal stability and ethnic variation in rates in Israel
Anticancer Res
Eye color and cutaneous nevi predict risk of ocular melanoma in Australia
Int J Cancer
Population-based incidence of uveal melanoma in various races and ethnic groups
Am J Ophthalmol
Cited by (344)
Incidence of Strabismus Post–Plaque Brachytherapy in Patients With Uveal Melanoma
2024, American Journal of OphthalmologyPseudomelanoma diagnosis in a tertiary ophthalmologic centre in Spain
2024, Canadian Journal of OphthalmologyImpact of COVID-19 on a rare disease (uveal melanoma) in a national reference unit of intraocular tumors in Spain
2023, Archivos de la Sociedad Espanola de OftalmologiaUveal melanoma in the Iranian population: two decades of patient management in a tertiary eye center
2024, International Journal of Retina and VitreousPatterns of radiological response to tebentafusp in patients with metastatic uveal melanoma
2024, Melanoma Research
Manuscript no. 2006-833.
Research supported by the EUROCARE-3 BIOMED-2 program, Brussels, Belgium (contract no. BMH4-CT98-3390); Compagnia di San Paolo, Torino, Italy; and European Community, Brussels, Belgium (grant no. SPC.2002303-DEP/01/19, “European Network of Cancer Registries: Survival of Adult Patients with Rare Tumors”). Dr Virgili’s work was partially supported by the Master of Epidemiology, University of Turin, Turin, Italy.
- ⁎
For a list of the members of the Group, see “Appendix” (available at http://aaojournal.org).